Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517373 · ClinicalTrials.gov registry record · Phase 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
NCT01517373 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 304 participants.
The verdict
NCT01517373, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
Study Summary
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
Interventions
- DRUG Placebo
- DRUG Glimepiride
- DRUG PF-04937319 10 mg
- DRUG PF-04937319 50 mg
- DRUG PF-04937319 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517373
The ClinicalTrials.gov registry entry for NCT01517373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01517373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517373 about?
NCT01517373 is a clinical study titled "Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin". This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
What is the current status of trial NCT01517373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2012-02. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01517373?
The interventions under investigation include: Placebo (DRUG), Glimepiride (DRUG), PF-04937319 10 mg (DRUG), PF-04937319 50 mg (DRUG), PF-04937319 100 mg (DRUG).
Who is sponsoring clinical trial NCT01517373?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.